ER-positive, HER2-negative, ESR1-mutated breast cancer

Estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated breast cancer is a distinct molecular subtype of mammary carcinoma affecting breast glandular tissue, most frequently identified in patients with locally advanced or metastatic disease These mutations typically arise as an acquired resistance mechanism under the selective pressure of prior anti-estrogen therapies, particularly aromatase inhibitors, causing constitutive, ligand-independent estr...

Estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated breast cancer is a distinct molecular subtype of mammary carcinoma affecting breast glandular tissue, most frequently identified in patients with locally advanced or metastatic disease

Estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated breast cancer is a distinct molecular subtype of mammary carcinoma affecting breast glandular tissue, most frequently identified in patients with locally advanced or metastatic disease Tumors express functional estrogen receptors without HER2 protein overexpression or gene amplification, but they harbor somatic activating mutations within the ligand-binding domain of the ESR1 gene These mutati...

Tumors express functional estrogen receptors without HER2 protein overexpression or gene amplification, but they harbor somatic activating mutations within the ligand-binding domain of the ESR1 gene

Tumors express functional estrogen receptors without HER2 protein overexpression or gene amplification, but they harbor somatic activating mutations within the ligand-binding domain of the ESR1 gene Clinically, this biomarker profile defines a state of endocrine therapy resistance, necessitating targeted interventions that effectively degrade or inhibit the mutated receptor complex